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Abstract: 
Diabetes is one of the major life threatening diseases worldwide. I t  c r e a t e s  m a j o r  h e a l t h  p r o b l e m s  i n  u r b a n  I n d i a .  G l y c o g e n  
Synthase Kinase-3 (GSK-3) protein of human is known for phosphorylating and inactivating glycogen synthase which also acts as a 
negative regulator in the hormonal control of glucose homeostasis. In traditional medicine, Momordica charantia is used as anti-
diabetic plant because of its hypoglycemic effect. Hence to block the active site of the GSK-3 protein three anti-diabetic compounds 
namely, charantin, momordenol & momordicilin were taken from Momordica charantia for docking study and calculation of binding 
energy. The aim of present investigation is to find the binding energy of three major insulin-like active compounds against 
glycogen synthase kinase-3 (GSK-3), one of the key proteins involved in carbohydrate metabolism, with the help of molecular 
docking using ExomeTM Horizon suite. The study recorded minimum binding energy by momordicilin in comparison to the others. 
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Background: 
Diabetes is a heterogeneous metabolic disorder characterized by 
altered carbohydrate, lipid and protein metabolism [1]. This can 
cause severe short-term and long-term consequences ranging 
from brain damage to amputations and heart disease [2]. 
Traditional plant remedies have always provided sources of 
useful hypoglycemic agents and therefore, should continue to 
be investigated for possible drug alternatives [3]. The increase 
in demand for the use of plant based medicines to treat diabetes 
may be due to the side effects associated with the use of 
orthodox drugs such as insulin and oral hypoglycemic agents. 
Effective control of blood glucose level is a key step in 
preventing or reversing diabetic complications and improving 
the quality of life in both type 1 and type 2 diabetic patients [4]. 
In our present study we have selected glycogen synthase 
kinase-3 (GSK-3) as a target for the inhibitors because of its 
unique multifunctional serine/threonine kinase activity and 
inactivation by phosphorylation. In response to insulin binding, 
PKB/AKT phosphorylates GSK-3 on serine 9, which prevents 
the enzyme from phosphorylating glycogen synthase [5-7]. 
Unphosphorylated glycogen synthase is active and able to 
synthesize glycogen. Thus it plays a key role in the transduction 
of regulatory and proliferative signals arising out at the cell 
membrane in the insulin signaling pathway, leading to 
potential modulation of blood glucose levels [8]. GSK-3 is also 
unique and it requires a substrate that has been phosphorylated 
by a distinct kinase before it can phosphorylate the substrate. In 
traditional medicine Momordica charantia, under the family 
cucurbitaceae is used as anti-diabetic plant because of its 
hypoglycemic effect. Polypeptide p, isolated from fruit, seeds 
and tissues of M. charantia showed significant hypoglycemic 
effect when administered subcutaneously to langurs and 
humans  [9]. The acetone extract of whole fruit powder of 
Momordica charantia in doses 25, 50, 75 mg/100g body weight BIOINFORMATION  open access 
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lowered the blood glucose from 13.30 to 50% after 8 to 30 days 
treatment in alloxan diabetic rats, confirming anti 
hyperglycemic activity of this plant in diabetic animals [10]. 
Oral administration of M. charantia could lead to the secretion of 
insulin from endocrine pancreatic beta cells [11-14].  Charantin, 
momordenol & momordicilin are some of the major active 
compounds, believed to possess insulin-like chemical structure 
and properties. In our present study glycogen synthase kinase-3 
(GSK-3), considered as a target for binding energy and docking 
study analysis against three of the active compounds using 
docking software, ExomeTM Horizon. The validation procedures 
are carried out and the interactions and scores are generated. 
 
 
Figure 1: Structures of the ligands (A) Charantin; (B) 
Momordenol; (C) Momordicilin 
 
Methodology: 
Protein Retrieval and Receptor Preparation 
Glycogen synthase kinase-3 (GSK-3) was downloaded from 
RCSB protein data bank having PDB ID 1Q5K (Figure 2) and 
selected for docking analysis. The water molecule and ligands 
attached with the protein were removed by Swiss PDV viewer. 
After removing the ligands and water molecules the refined 
protein was saved in PDB format. 
 
Ligand Preparation and ADMET properties Analysis 
The refined protein structure was taken for Docking with 
selected ligands. All the ligands Table 1 (see supplementary 
material). Were drawn using MOLDRAW tool of Exome TM 
Horizon [15]. Then ligands were filtered using ADMET tools of 
Exome TM Horizon software for checking drug likeliness by 
different rules of lipinski rule [16]. All the ligands that satisfy 
lipinki’s rule is also provided Table 1 (see supplementary 
material). 
 
Binding Site Analysis and Grid Preparation 
The active site and grid map of the receptor was done by of 
Exome TM Horizon and total eight active sites were identified. 
Residues of the active sites were shown both in molecule as 
well graphical structure and grid map result were shown in 
Table 2 (see supplementary material).  The spacing of grid was 
set as 1.00 Ao and the no. of grid point was taken as 60 x 60 x 60 
Ao. 
 
Protein Ligand Interaction studies 
The protein-ligand docking was performed using Lamarckian 
genetic algorithm using default parameter [17, 18]. This is the 
same as the standard genetic algorithm except that, before 
scoring, each conformation (gene) is subjected to energy 
minimization. The next population is then originated by 
members of energy-minimized population. The name 
"Lamarckian" refers to the failed genetic theory of Jean-Baptiste 
Lamarck, who held that an organism could pass on changed 
experienced in its lifetime to its offspring. This theory was 
eventually abandoned in favor of Mendel's now familiar laws of 
inheritance. The LGA is faster than both simulated annealing 
and the standard genetic algorithm, and it allows the docking of 
ligands with more degrees of freedom. The number of 
automated docking runs, number of individuals in the 
population, maximum number of energy evaluations and 
number of generations were set to 10, 50, 2500 and 3000 
respectively. All the molecules successfully docked to the 
binding site. 
 
 
Figure 2: Structure of the target (1Q5K) 
 
Discussion: 
In insulin signaling pathway, the phosphorylation of glycogen 
synthase by GSK-3 involves the priming phosphorylation by a 
distinct kinase to facilitate the binding of the substrate to the 
kinase. The importance of protein phosphorylation as a main 
regulatory mechanism used by cells to regulate enzymes and 
other proteins and the association of many maladies with its 
aberrations make kinases to be important targets and the hunt 
for kinase inhibitors has attracted a great attention in drug 
discovery in recent years. Hence to block the phosphorylation 
activity of GSK-3 (1Q5K) three active compounds of Momordica 
charantia  were used. The protein structure was having 689 
groups, 5515 atoms and 5695 bonds. The ligands (Figure 1) 
selected for docking studies and the corresponding interaction 
energies are given in Table 2 (see supplementary material). BIOINFORMATION  open access 
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The active site of 1Q5K offers many different binding modes for 
these compounds. The active sites from H1 to H8 were found to 
be IGNGGVVKQNCD, LDPVDPPALHAR, QPIFEKVHKVF, 
LHTSSIVRLTPP, VLGQWCSRLEY, FKLQKNRELFGS, 
VYRARHSRYGQPE and PIFGGVEF.  All the ligands were 
docked into the active sites of the protein and the resulted 
binding energy scores that ranges from -2.42 to -5.48 kcal/mol. 
After docking study it was observed that these compounds 
successfully bind with GSK-3 as a result it may prevent the 
phosphorylation of glycogen synthase for which the production 
of glycogen will continue and maintain the glucose level. From 
the calculation of binding energy it was found that the 
compound momordicilin was found to be the most active 
compound and having minimum binding energy in all the 
active sites. The ADMET prediction of momordicilin showed 
good result with least number of violations Table 1 (see 
supplementary material). From this result, we can suggest that 
momordicilin is a potent inhibitor of glycogen synthase kinase-
3 and can be used as the major anti-diabetic compound form M. 
charantia. The H7 active site of GSK-3 containing 
VYRARHSRYGQPE residues was identified as the most 
favorable binding site for all the ligands, so H7 site can be used 
as the major target site for the anti-diabetic compounds. 
 
Conclusion: 
In the present work we docked the ligands, charantin, 
momordenol & momordicilin from the medicinal plant 
Momordica charantia with the protein glycogen synthase kinase-
3, one of the key targets for Type 2 diabetes and momordicilin 
found as the most active compound in the respective target site. 
Further investigation in this line of research may include 
docking studies with other targets involved in carbohydrate 
metabolism. The predicted information is hoped to help for 
understanding the mechanisms of these plant based three anti-
diabetic compounds for the treatment of diabetics cost 
effectively. Based on this successful identification of plant-
derived anti-diabetic drug candidates, we can look forward to 
further successes in this research area in the future. 
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Supplementary Material: 
 
Table 1: The ligands were taken from the plant Momordica charantia. The molecular weights are calculated and given in column 4. 
The ligands that show passing Lipinski’s filter based on colors in column 5 and bioavailabilty in column 6.   
Sl.no. Compound 
Name 
IUPAC Name  Molecular 
Weight 
Lipinki’s 
Filter 
Bioavailability 
1  Charantin  (2S, 3R, 4R, 6R)-5(10.13-dimethyl-17-(6-methylheptan-2-
yl)-hexadecahydro-1H-cyclopenta[a]phenathren-3-yloxy)-
6-(hydroxymethyl)-tetrahydro-2H-pyran-2,3,4,5-tetracol 
574.83 Blue Red  (Six) 
2 Momordenol  17-(5-ethyl-6-methylheptan-2-yl)-3-hydroxy-9, 13-
dimethyl-1,3,4,7,8,10,11,13,17-decahydro-2H-
cyclopenta[a]-16(9H)-one 
426.35 Blue Red  (Six) 
3 Momordicilin  (E)-4-((2-hydroxyhex-3-en-2-yloxy)methyl)-
4,6a,6b,8a,11,12,14b-heptamethyl-octadecahydropicen-
3(4H.6bH,14bH)-one 
540.86 Yellow  Red  (Five) 
 
Table 2: The active site of the receptor (1Q5K), the grid values taken for docking study and the minimum binding energy of the 
ligands. 
Active 
Site 
Residues  Center of Grid 
Value 
Minimum Binding Energy (kcal/mol) of the Selected 
Compounds 
Charantin, Momordenol Momordicilin 
H1 IGNGGVVKQNCD
  
20.411, 27.175, 
11.723 
-2.67   -3.92  -4.81 
H2 LDPVDPPALHAR
  
29.722, 30.136, -
17.358 
-2.95   -3.92  -3.64 
H3 QPIFEKVHKVF  38.201,  49.261, 
12.182 
-3.05 -3.56    -5.48 
H4 LHTSSIVRLTPP  15.615,  47.909,  -
1.702 
-2.50 Nil  Nil 
H5  VLGQWCSRLEY  29.722,  57.083,  3.762  -2.57 -3.31 -4.22 
H6  FKLQKNRELFGS  8.603, 31.714, 13.371  -2.75  -3.50  -4.72 
H7 VYRARHSRYGQPE  34.920,  34.918, 
12.531 
-4.25 -4.06 -4.08 
H8 PIFGGVEF  20.499,  54.988, 
20.671 
-2.42 -4.06 -4.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 